PTEN and neoplasm: K163 increased acetylation by treatment with HDAC inhibitors, reduced active pAKT levels, and impaired tumor growth in WT-PTEN-expressing cells compared to (acetylation-resistant) PTEN-K163R-expressing cells [52].